HeartWare Continues To Wrestle With MVAD Trial, And May Need A New Study
This article was originally published in The Gray Sheet
More pump thrombus events identified in December in HeartWare International's MVADvantage trial for its miniaturized ventricular assist device are forcing the firm to consider whether the European study is salvageable or whether a new trial needs to be launched. Also, updates on the firm's HVAD progress and financials from the JP Morgan Healthcare Conference.
Register for our free email digests: